SB 11736 / UT Southwestern Medical Center, AstraZeneca, Sino Biopharm - LARVOL DELTA

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates (Businesswire) - "The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and commercialization in global markets excluding China, Hong Kong, Taiwan, Macau, and Republic of Korea."

Licensing / partnership • Crohn's disease • Ulcerative Colitis